Further elucidation of the driving processes of innate immune cell activation in CAVD, including trained immunity and CHIP, might identify novel therapeutic targets that can be used for prevention and treatment of CAVD. This evidence concerns the gene STUB1 and congenital bilateral aplasia of vas deferens from CFTR mutation.